Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Australia / NCT06546592
Recruiting Not applicable

Locally Optimised Contouring With AI Technology for Radiotherapy

NCT06546592 · tracked via the Priya Life Science Australia tracker
Sponsor
Royal North Shore Hospital
Phase
Not applicable
Started
2025-02-11
Last updated
2026-01-29

Condition(s) studied

ContouringSegmentationRadiation TherapyArtificial IntelligenceDeep Learning

Investigational drug(s) / intervention(s)

AI assisted contouring

AI assisted contouring: Initial are generated automatically using software powered by artificial intelligence

Study summary

LOCATOR is a multicentre phase II randomised clinical trial that is looking at the process of contouring in radiation treatment for breast cancer patients. This study looks at whether contouring aided by artificial intelligence (AI) is comparable in quality to that of contouring done completely manually by a radiation oncologist. We are also looking at whether AI assisted contouring saves radiation oncologists time when compared to fully manual contouring.

LOCATOR uses the LOCATOR software which is an in-house software developed locally and trained on local data.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * 18 years and older who are planned for primary breast malignancy * ECOG performance 0-2 * Ability to understand and willingness to sign a written informed consent document * The target volume must be able to be objectively reviewed by current published national or international clinical guidelines Exclusion Criteria: * Patients under 18 years of age * Patients unable to understand consent documents

Primary outcome measure(s)

  • Assessment of differences in Contour Quality — 18 months
    To assess the contour quality of fully manual segmentation vs AI assisted segmentation. This assessment will be done using the MD Anderson Cancer Centre five-point likert scale used to validate autosegmentation models ranging from (Strongly disagree to Strongly Agree). The measure will be the proportion of unacceptable contours (as defined by MD Anderson autocontouring score \<= 2) between manual contouring and AI-assisted contouring.

Trial sites (3)

FacilityCityRegionStatus
Western Cancer Centre Dubbo Dubbo New South Wales Recruiting
Central West Cancer Centre Orange New South Wales Recruiting
Department of Radiation Oncology, Royal North Shore Hospital St Leonards New South Wales Recruiting

More Royal North Shore Hospital trials in Australia

Pelvis Adaptive Radiotherapy (ART) Recruiting
Positioning of Esketamine Treatment in the Real-world Management of Depression Recruiting
The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab Recruiting
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking Active, not recruiting
Continuous Monitoring of Prostate Position During Radiotherapy Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06546592 on ClinicalTrials.gov ↗ ← All trials in Australia